Not medical advice. Talk to your provider before using any peptide. Full disclaimer
CJC-1295 + Ipamorelin
Beginner tier: 200 mcg, daily · 12w on / 4w off · community consensus
Also known as: CJC/Ipa, CJC-1295/Ipamorelin, mod GRF 1-29 + Ipamorelin
Hundreds of threads on r/Peptides call this the cleanest growth hormone stack available without a prescription. CJC-1295 (No DAC) plus Ipamorelin is a pre-mixed blend hitting two separate pituitary receptors, GHRH and GHS-R1a; community reports describe a GH pulse that neither achieves alone. Ipamorelin's selectivity is the draw. Unlike GHRP-2 or GHRP-6, it didn't raise ACTH or cortisol in swine (Raun et al. 1998)[1]. Sleep improvements typically appear within seven to ten days. No published RCT has tested this exact combination. The evidence base leans on individual-component clinical data combined with community experience across thousands of users.
What Is CJC-1295 + Ipamorelin?
Deeper sleep in under two weeks. That's the benefit users mention first, and it's the reason CJC-1295 plus Ipamorelin (also called CJC/Ipa or modified GRF 1-29 plus Ipamorelin) has become the default GH secretagogue stack for anti-aging and body recomposition protocols.
The blend contains two peptides in a single vial. CJC-1295 without DAC is a 29-amino-acid GHRH analog. Ipamorelin is a pentapeptide ghrelin mimetic. Only ipamorelin has human data in the form used here. Gobburu's group [3] infused it into healthy men, and GH peaked at about 40 minutes. CJC-1295 without DAC has no published human trial. Teichman et al. (2006)[2] tested CJC-1295 with DAC, a different long-acting form. One injection raised GH 2 to 10-fold for 6 days or more and IGF-1 1.5 to 3-fold for 9 to 11 days. In rats and swine, Raun's group [1] found ipamorelin released GH without raising ACTH or cortisol.
CJC-1295 sets the amplitude of the GH pulse through the GHRH receptor. Ipamorelin triggers the release through GHS-R1a. Together, the resulting pulse exceeds what either produces independently.
Community dosing uses three tiers of total blend per injection. Beginner is 200 mcg once daily, Moderate 300 mcg once daily, and Aggressive 600 mcg twice daily. Injections go in subcutaneously on an empty stomach, the once-daily dose before bed. The standard cycle runs 12 to 16 weeks on, 4 weeks off. Hundreds of r/Peptides threads (roughly 95,000 members) report consistent improvements in sleep quality, recovery speed, skin texture, and gradual fat loss over three to four months.
The limitation is straightforward: no published randomized controlled trial has studied this pre-mixed combination in humans. Combination benefit is mechanistically sound but clinically unquantified. All human GH-elevation data comes from each component tested separately.
How CJC-1295 + Ipamorelin Works
Two receptors, one coordinated pulse. That is the core idea.
CJC-1295 (No DAC) binds the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells. This activates Gs-coupled adenylyl cyclase, raises intracellular cAMP, and primes the cell for GH synthesis. Think of it as loading the spring.
Ipamorelin binds a separate receptor: GHS-R1a. That activation runs through Gq/11 signaling. Intracellular calcium rises via IP3, directly triggering GH exocytosis. This pulls the trigger.
When both pathways fire at the same time, the GH pulse is larger than either agent produces alone. GHRH sets amplitude; the ghrelin mimetic sets timing. Gobburu et al. (1999)[3] mapped ipamorelin's pharmacokinetics in healthy men given 15-minute IV infusions. GH peaked at about 40 minutes, and ipamorelin's half-life was 2 hours.
Ipamorelin's selectivity separates it from older GHRPs. GHRP-2 and GHRP-6 also bind GHS-R1a, and in swine they raised ACTH and cortisol. Ipamorelin did not, even at doses over 200 times the amount needed for GH release (Raun et al. 1998)[1].
Downstream, the raised GH pulse stimulates hepatic IGF-1 production. IGF-1 drives anabolic effects in muscle, bone, and connective tissue. GH also activates hormone-sensitive lipase in adipocytes, promoting lipolysis. The combined release follows the body's natural pulsatile GH pattern rather than a sustained plateau, preserving negative feedback regulation through the hypothalamic-pituitary axis.
CJC-1295 + Ipamorelin Benefits
- CJC-1295 plus Ipamorelin benefits center on clean GH release and the downstream effects it drives.
- Dramatically improved sleep depth is the most consistently cited effect, with onset typically within 7 to 14 days. Community forums show this as the single most mentioned benefit across hundreds of threads on r/Peptides.
- A cleaner hormonal profile than older GHRPs. In swine, ipamorelin left ACTH, cortisol and prolactin unchanged (Raun et al. 1998)[1]. Users credit that selectivity for tolerating 12 to 16 week cycles.
- Gradual fat loss combined with lean mass gains over 3 to 4 months, particularly abdominal fat. Users on standard cycles report visible recomposition by weeks 8 to 12.
- Faster recovery from training and injury. GH and IGF-1 elevation accelerates protein synthesis in muscle and connective tissue; community reports consistently place recovery improvement at weeks three through four.
- Skin, hair, and nail quality improvements typically appear by month two. Collagen synthesis driven by sustained IGF-1 elevation produces visible changes that many users notice before body composition shifts.
- Pre-mixed convenience: one vial, one injection, two pathways activated. The blend removes the complexity of sourcing and mixing two separate peptides.
CJC-1295 + Ipamorelin: Science vs Community Consensus
CJC-1295 (No DAC) acts on the GHRH receptor but has no published human trial; the human CJC-1295 data come from the DAC form.
Read the evidence (key study, limitations)
Ipamorelin released GH via GHS-R1a without raising ACTH or cortisol in swine, and a human PK study found a single GH peak [3]. No published RCT has tested the combination as a co-administered blend. The combined effect is mechanistically sound (GHRH + ghrelin receptor dual-pathway) but clinically unquantified.
Teichman et al. 2006 (PMID 16352683) tested CJC-1295 with DAC, not the No DAC form in this blend. One SC injection raised GH 2–10x for 6+ days and IGF-1 1.5–3x for 9–11 days in healthy adults. Raun et al. 1998 (PMID 9849822): ipamorelin released GH without raising ACTH or cortisol in swine, even at over 200 times its GH-releasing dose.
All human GH-elevation data is for individual components, not the pre-mixed blend. CJC-1295 studies used the With-DAC form (longer half-life); No DAC combination dosing extrapolated by community. No Phase III trial for either compound. No long-term (>6 month) safety data in humans.
Widely regarded as the best "clean" GH stack: high satisfaction for sleep quality, body recomposition, and recovery.
Read the reports (what users report 5, common issues 5)
Bedtime dosing on empty stomach is near-universal. Strong consensus on No DAC over DAC for daily-pulse protocols.
- Dramatically improved sleep depth: most commonly cited, onset within 1–2 weeks
- Clean GH profile: no hunger spike, no cortisol or prolactin elevation (vs GHRP-2/GHRP-6)
- Gradual fat loss + lean mass gain over 3–4 months
- Faster recovery from training and injury
- Improved skin quality and sense of well-being by month 2
- Water retention / mild edema in hands, feet, wrists: common in weeks 1–4
- Slow timeline: users expecting fast results often quit before meaningful changes appear (minimum 4–6 weeks)
- DAC vs. No DAC confusion: products mislabeled; DAC form has 6–8 day half-life, not suitable for daily pulse dosing
- Tingling and numbness in extremities: GH-induced fluid shifts; resolves after initial weeks
- Cost and consistency of pre-mixed blends; purity varies significantly by brand
Human trials studied each part on its own. CJC-1295 with DAC, not the No DAC form in this blend, raised GH and IGF-1 in healthy adults (PMID 16352683). IV ipamorelin raised GH in a human PK study (PMID 10496658). No trial has tested the blend. Community dosing (200 to 600 mcg of total blend per injection) cannot be compared directly with trial doses, which were per kilogram. Main divergence: community uses daily No DAC pulses while the only long-duration human data used the DAC form.
CJC-1295 + Ipamorelin Dosage Guide
Standard vials come as 10 mg total (5 mg CJC-1295 No DAC plus 5 mg Ipamorelin). Add 2 mL bacteriostatic water. That gives you 5,000 mcg/mL total peptide concentration.
At 200 mcg per dose: 0.04 mL = 4 units on a 100-unit insulin syringe. One vial lasts about 50 doses. At 300 mcg: 0.06 mL = 6 units. One vial gives about 33 doses. At 600 mcg: 0.12 mL = 12 units. One vial yields about 16 injections.
Empty stomach is non-negotiable. Food within two hours raises somatostatin, which directly blunts the GH response. Wait at least 30 minutes after injecting before eating.
The biggest beginner mistake: using "CJC-1295" without confirming it is the No DAC version. The DAC form has a 6 to 8 day half-life and should only be dosed once or twice per week. Daily dosing of the DAC form creates continuous non-pulsatile GH elevation, defeating the purpose.
Store reconstituted vials at 2 to 8 degrees Celsius. Use within 21 to 28 days. Cloudiness or particulates means something went wrong; don't inject.
Cycling Protocol
Standard protocol is 12-16 weeks on, followed by 4 weeks off to maintain GHS-R1a receptor sensitivity. Some users run 5 days on / 2 days off within each cycle week. Dose before bed on an empty stomach (at least 2 hours fasted) to align with natural nocturnal GH pulsatility. Avoid eating for 30 minutes post-injection to prevent insulin-mediated blunting of GH release.
Ipamorelin (GHS-R1a agonist) is the primary desensitization driver. Continuous GHS-R1a stimulation leads to receptor downregulation and β-arrestin-mediated internalization, reducing the GH pulse magnitude over time. GHRP-2 desensitization data (Nijland et al. 1998, PMID 9820615) showed a 38% decline in peak GH from day 1 to day 5 with daily dosing. The 5 days on / 2 days off sub-pattern partially mitigates this. The 4-week off period allows receptor re-sensitization. CJC-1295 No DAC (GHRHR agonist) also undergoes receptor desensitization with repeated stimulation but the process is slower.
- Diminishing sleep quality improvement that was initially strong
- Reduced injection-site warmth or flushing response (proxy for acute GH release)
- IGF-1 trending down despite continuing the same dose
- Reduced recovery benefit compared to earlier in the cycle
Or use the universal Peptide Calculator for any peptide.
CJC-1295 + Ipamorelin Protocols by Goal
Expected: Improved sleep depth by week 2; mild fat loss and recovery improvement by weeks 6–8; body composition shifts by end of cycle
Monitor: Baseline and post-cycle IGF-1 recommended if running multiple cycles; fasting glucose monitoring if diabetic risk factors present
How to Use CJC-1295 + Ipamorelin
- 1Step 1
Gather supplies: reconstituted CJC/Ipa vial, 29 to 31 gauge insulin syringe (100-unit), alcohol swabs.
- 2Clean the vial stopper with an alcohol swab
Draw air into the syringe equal to your dose volume, inject air into the vial, then draw your dose.
- 3For a 200 mcg dose: draw to the 4-unit mark (0.04 mL)
For 300 mcg: 6 units (0.06 mL). For 600 mcg: 12 units (0.12 mL). These numbers assume a 10 mg vial reconstituted with 2 mL bacteriostatic water (5,000 mcg/mL).
- 4Step 4
Choose your injection site: lower abdomen about two inches from the navel, or upper outer thigh. Clean the site with an alcohol swab.
- 5Step 5
Pinch a fold of skin, insert the needle at a 45 to 90 degree angle, and inject slowly. Release the skin fold after withdrawing.
- 6Step 6
Rotate injection sites each time to prevent lipodystrophy.
- 7Step 7
Timing: 30 minutes before sleep on an empty stomach (minimum 2 hours fasted). Don't eat for 30 minutes after injection. Optional second dose on training days, post-workout while still fasted.
- 8Step 8
Return the vial to the refrigerator immediately (2 to 8 degrees Celsius).
Alternative Routes
Reference route; all dosing guidelines apply
Lower abdomen or upper thigh preferred; 29–31 gauge insulin syringe; inject on empty stomach. SC bioavailability has not been measured in humans for either component
Absorption highly variable; no validated dose for the blend
Intranasal GHRP-2 has been studied in 15 children (Pihoker 1997, PMID 9390009). Nasal ipamorelin has rat data only, about 20% bioavailability (Johansen 1998, PMID 9879640), and CJC-1295 has none. Not recommended: no reliable dose conversion available for the blend.
CJC-1295 + Ipamorelin Stacking Protocols
Works With
Most popular stack: GH secretagogue creates anabolic/repair environment while BPC-157 accelerates local tissue healing. Known as part of the "Wolverine Stack."
BPC-157 250–500 mcg SC near injury site (AM); CJC/Ipa blend (bedtime)
Systemic connective tissue and tendon repair complement. Combined with BPC-157 as the full Wolverine Stack for injury recovery.
TB-500 2–5 mg SC 2x/week (AM); CJC/Ipa blend (bedtime)
AOD-9604 (GH fragment 177–191) adds targeted lipolytic activity without the IGF-1 elevation of full GH; combined with CJC/Ipa for enhanced fat loss in body recomp protocols.
300 mcg AOD-9604 SC fasted AM; CJC/Ipa blend bedtime
Some users alternate cycles of Sermorelin (GHRH 1-29 analog) with CJC-1295 No DAC to preserve GHRH-receptor sensitivity over longer timeframes. Not typically co-administered.
Cycle sermorelin as a substitute GHRH rather than concurrent stack
Avoid
Adding a second GHS-R1a agonist (GHRP-2) on top of Ipamorelin stacks two drugs on one receptor, with increased cortisol, prolactin, and appetite stimulation; raises IGF-1 unpredictably. Not recommended without medical supervision.
Same receptor competition/addition concern as GHRP-2 plus significant hunger amplification. Unlikely to add meaningful benefit over ipamorelin already in the blend.
CJC-1295 DAC has a 6–8 day half-life and is not dosed daily: combining with the No DAC blend creates dosing schedule confusion and unpredictable GHRH receptor stimulation duration.
Do not combineMK-677 is a long-acting oral GHS-R1a agonist (t½ ~24h); stacking with Ipamorelin in this blend creates continuous receptor activation, negating the pulsatile GH release benefit and substantially elevating IGF-1 and cortisol. Common community mistake.
Estimated Cost
Pricing updated 2026-04-09
CJC-1295 + Ipamorelin Side Effects
GH antagonizes insulin. That is the most important safety consideration with any GH secretagogue stack, and it deserves to lead this section.
Raised fasting glucose, worsening insulin sensitivity, and rising HOMA-IR are real risks at higher doses and in users with pre-diabetic markers. If fasting glucose rises more than 20 mg/dL from baseline, reduce the dose or stop the cycle. Pre-diabetic users should monitor HbA1c across consecutive cycles.
Water retention is the most common complaint in the first four weeks. Mild edema in the hands, wrists, and feet affects a large percentage of users. GH promotes sodium retention in the kidneys. Most cases resolve after the initial adaptation period. If edema persists beyond week four, reducing the dose by 25 to 50 percent and limiting injection to once-daily bedtime typically resolves it.
Tingling and numbness in the fingers and hands reflect GH-mediated fluid shifts causing mild carpal tunnel compression. Community reports consistently describe this in the first month. At 200 to 400 mcg of total blend, the effect is usually transient. If symptoms persist beyond two weeks after reducing the dose by half, stop the cycle. Carpal tunnel that won't resolve warrants medical evaluation.
Facial flushing right after injection is common in community reports and typically lasts 5 to 15 minutes. FDA's Category 2 page lists serious adverse events tied to CJC-1295, including increased heart rate and a systemic vasodilatory reaction. For ipamorelin, FDA cites serious adverse events, including death, in a published study of IV ipamorelin for gastric motility. Mild headache follows some users' early injections but rarely continues past the first week.
Published human safety data exists for each component individually, not the pre-mixed blend. CJC-1295 without DAC, the form in this blend, has no published human trial. Teichman et al. (2006)[2] tested CJC-1295 with DAC and reported no serious adverse reactions. Ipamorelin has human pharmacokinetic data from IV infusions in healthy men (Gobburu et al. 1999)[3]. Raun et al. (1998)[1] worked in rats and swine. No long-term safety study exceeding six months exists for either compound.
Community-reported issues beyond the above include vivid dreams (common, generally considered positive), occasional lightheadedness post-injection, and frustration with slow timelines. Meaningful body composition changes take a minimum of four to six weeks.
Cancer is an absolute contraindication. GH promotes cell proliferation. Active malignancy or a history of cancer rules out use. Active pituitary tumors and intracranial neoplasms also preclude use.
Diabetes mellitus is a contraindication. GH antagonizes insulin action and will worsen glycemic control in uncontrolled diabetics. Diabetic retinopathy adds further risk because GH and IGF-1 may accelerate retinal neovascularization.
Pregnancy and breastfeeding: absolute contraindication. No reproductive safety data exists for either component.
GH accelerates T4-to-T3 conversion. If you have subclinical hypothyroidism or take thyroid medication, monitor thyroid function mid-cycle.
When to stop: worsening fasting glucose, carpal tunnel persisting beyond two weeks at a reduced dose, edema unresponsive to dose reduction, or any new tumor diagnosis. When to see a doctor: IGF-1 above 400 ng/mL, glucose problems you can't resolve with dose changes, or any symptom that feels disproportionate.
Common Issues & Solutions
Water retention (edema in hands/wrists) during weeks 1–4: lower the dose by 25–50%; ensure empty stomach at injection; usually self-resolves. Persistent edema suggests GH-induced sodium retention: reduce to once-daily bedtime only.
No effect after 4+ weeks: most common cause is insufficient fasting window (food within 2 hours raises somatostatin); second cause is poor-quality or mislabeled peptide (DAC form sold as No DAC).
Tingling or numbness in fingers/hands: classic GH-mediated fluid shift causing mild carpal tunnel syndrome. Lower dose by 50%; if persists >2 weeks at reduced dose, stop the cycle.
Elevated fasting glucose: GH antagonizes insulin action; if fasting glucose rises >20 mg/dL from baseline, reduce dose or stop. Monitor HbA1c in pre-diabetic users.
DAC vs. No DAC confusion: the pre-mixed blend always uses No DAC (CJC-1295 without the Drug Affinity Complex); a certificate of analysis confirms which form is in the vial. DAC form should only be dosed 1–2x per week due to 6–8 day half-life: daily dosing of DAC form causes continuous non-pulsatile GH elevation.
Ask AI about this page
Ask AI for a second opinion on CJC-1295 + Ipamorelin dosing and side effects
Contraindications
- Active cancer or history of malignancy: GH promotes cell proliferation
- Diabetes mellitus: GH antagonizes insulin and may worsen glycemic control
- Pregnancy or breastfeeding
- Active pituitary tumors or other intracranial neoplasms
- Hypersensitivity to GHRH analogs or ghrelin mimetics
Drug Interactions
- Insulin and oral hypoglycemics: GH release antagonizes insulin action; blood glucose monitoring required
- Corticosteroids: may blunt GH response and counteract benefits; chronic use reduces efficacy
- Other GH secretagogues (GHRP-2, GHRP-6, sermorelin): additive GH release increases side effect risk; avoid stacking without medical supervision
- Thyroid hormones: GH can accelerate T4-to-T3 conversion; monitor thyroid function
- CYP450-metabolized drugs: GH may alter hepatic clearance of drugs metabolized by CYP3A4
- Adding a second GHS-R1a agonist (GHRP-2) on top of Ipamorelin stacks two drugs on one receptor, with increased cortisol, prolactin, and appetite stimulation; raises IGF-1 unpredictably. Not recommended without medical supervision.
- Same receptor competition/addition concern as GHRP-2 plus significant hunger amplification. Unlikely to add meaningful benefit over ipamorelin already in the blend.
- CJC-1295 DAC has a 6–8 day half-life and is not dosed daily: combining with the No DAC blend creates dosing schedule confusion and unpredictable GHRH receptor stimulation duration.
- MK-677 is a long-acting oral GHS-R1a agonist (t½ ~24h); stacking with Ipamorelin in this blend creates continuous receptor activation, negating the pulsatile GH release benefit and substantially elevating IGF-1 and cortisol. Common community mistake.
Product Quality
Pre-mixed blends add one layer of risk on top of single-peptide quality concerns: the CJC/Ipa ratio in the vial must be verified, and DAC vs. No DAC mislabeling is a documented problem in the research peptide market. Purity testing surveys find ~20–30% of unverified peptide products fail purity standards. FDA enforcement actions in 2024 targeted research peptide companies marketing for human use.
- A useful Certificate of Analysis (CoA) shows HPLC purity >98% for each component independently
- "No DAC" vs. "with DAC": the exact sequence settles it; No DAC = modified GRF(1-29)
- Third-party testing (Janoshik or an equivalent independent lab) is the only outside check; unmarked vials carry unknown contents
- Verify the 50/50 blend ratio is certified: some products are mixed at non-equal ratios
- Reconstituted vials should be clear; cloudiness or particulates indicate degradation or contamination
- A "research use only" label on research-grade products is required by law; clinics using "FDA-approved" language for this compound are making a false claim
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| IGF-1 (Insulin-Like Growth Factor 1) | Baseline before starting; at week 8–12; after each cycle | Age-adjusted normal range (typically 100–300 ng/mL depending on age); protocol target: upper-normal or slightly above for anti-aging; >400 ng/mL warrants dose reduction |
| Fasting glucose and fasting insulin | Baseline; monthly during cycle, especially at higher doses | Fasting glucose <100 mg/dL; HOMA-IR <2.0 |
| HbA1c | Baseline and end of each cycle if running multiple consecutive cycles | <5.7% |
| Thyroid panel (TSH, Free T3, Free T4) | Baseline; mid-cycle if symptomatic (fatigue, cold intolerance) | Not listed |
| Blood pressure | Baseline and monthly if stacking with anabolics or in hypertensive patients | Not listed |
Primary downstream marker of GH axis activation; confirms biological response and detects supraphysiological elevation
GH antagonizes insulin signaling; chronic GH elevation can induce insulin resistance (GH-mediated glucose intolerance)
Detects cumulative insulin resistance effects not visible in single fasting glucose readings
GH accelerates T4-to-T3 conversion; may unmask subclinical hypothyroidism or require thyroid medication adjustment
GH-induced sodium retention can elevate blood pressure, particularly in susceptible individuals
CJC-1295 + Ipamorelin Before and After
Improved sleep quality and deeper REM cycles. Mild water retention possible as GH levels rise.
Faster recovery from training. Skin and hair quality begin to improve. Increased energy and mood stability.
Noticeable body composition changes: reduced abdominal fat, improved muscle tone. Joint and connective tissue recovery.
Full anti-aging benefits emerge: improved skin elasticity, sustained fat loss, enhanced exercise capacity.
Benefits plateau. Cycle off for 4 weeks to maintain receptor sensitivity before restarting.
What to Expect
Week 1 to 2, sleep and early adaptation. GH pulses begin rising within hours of the first injection; in a human ipamorelin study, GH peaked about 40 minutes after dosing [3]. Most users notice deeper sleep and vivid dreams within seven to ten days. Mild water retention and facial flushing after injection are common. IGF-1 starts climbing by day three to five with repeated dosing.
Weeks 3 to 4, recovery picks up. Training recovery improves noticeably. Energy and mood stabilize. Skin texture starts changing. Water retention may peak around this point before beginning to resolve. GH-mediated fat oxidation has started, though body composition changes aren't visible yet.
Months 2 to 3, body recomposition becomes visible. Abdominal fat reduces. Muscle fullness improves. Joints and connective tissue feel noticeably better. Libido often improves. Sustained IGF-1 elevation is driving protein synthesis and lipolysis at the same time.
Months 3 to 4, peak benefits. Skin elasticity improves measurably. Hair and nail growth may pick up. Fat loss continues while lean mass holds. Side effects are typically minimal by this stage if the dose is well-calibrated.
Month 5 and beyond, benefits plateau. GHS-R1a desensitization becomes the limiting factor with uninterrupted use. Four weeks off allows receptor re-sensitization. Community users consistently report the next cycle works just as well after a proper break. Fat loss gains are largely retained during the off period; water-based lean mass may recede temporarily.
Detailed Timeline: Science vs Community
GH rises within an hour of a dose (IV ipamorelin peak ~40 min, PMID 10496658); IGF-1 begins rising by day 3–5 with repeated dosing
Noticeably deeper sleep and vivid dreams are the most consistent early reports; mild water retention and bloating common
IGF-1 approaching new plateau; GH-mediated lipolysis initiated; protein synthesis upregulation beginning
Faster recovery between training sessions; improved energy and mood; skin texture beginning to improve; water retention may persist or start resolving
Sustained IGF-1 elevation drives muscle protein synthesis; GH-mediated lipolysis (hormone-sensitive lipase activation) produces measurable fat loss
Visible fat loss especially abdominal; improved muscle fullness; joint and connective tissue feel notably better; libido often improves
Maximum cumulative tissue response; anti-aging markers (skin elasticity, collagen synthesis) measurable
Body composition changes most visible; hair and nail growth may accelerate; sustained fat loss with preserved lean mass; anti-aging effects become apparent
GHS-R1a desensitization risk increases with uninterrupted use; 4-week off period allows receptor upregulation
Benefits plateau; some regression of water-based lean mass when off; fat loss gains largely retained; users report next cycle works comparably after 4-week break
Pharmacokinetics
Source: Ipamorelin t½ ~2h drives dosing frequency (Gobburu et al. 1999, PMID 10496658); CJC-1295 No DAC t½ ~30 min (estimated, never measured in humans)
Pharmacokinetics: Active Dose Over Time
t½ = ~2 hours (ipamorelin); ~30 min (CJC-1295 no DAC, never measured in humans)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is CJC-1295 + Ipamorelin Legal?
CJC-1295 and Ipamorelin are not FDA-approved for any therapeutic use. Both are classified as research-only compounds in the United States. Research-grade products must carry "for research use only" labeling and may not be marketed for human consumption.
Neither peptide is on FDA's 503A bulks list. FDA's Category 2 page (captured October 6, 2026) lists CJC-1295 and ipamorelin acetate as nominated but withdrawn. Ipamorelin acetate also sits in 503B Category 2, added September 29, 2023. No FDA rule adds either one to the 503A bulks list. Any company or clinic claiming "FDA approval" for this combination is making a false statement.
Both peptides appear on the WADA Prohibited List under S2 (Peptide Hormones and Related Substances). Anti-doping labs have built urine tests for CJC-1295 using spiked samples [4], and one was validated to WADA standards [5]. A lab detected ipamorelin and its metabolites in urine after a nasal dose in one volunteer [6]. Athletes subject to drug testing should not use this compound.
FDA enforcement actions in 2024 targeted research peptide companies marketing products for human use. The regulatory environment around research peptides continues to shift.
This content is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before using any peptide compound.
Who Should Consider CJC-1295 + Ipamorelin
- Adults over 30 seeking anti-aging and recovery benefits
- Athletes and bodybuilders optimizing body composition and recovery
- Adults with age-related GH decline (somatopause)
- Individuals with poor sleep quality seeking deeper restorative sleep
- Post-injury patients wanting accelerated tissue repair
Related Peptides
What Changed for CJC-1295 + Ipamorelin
- Evidence
Corrected Oct 17, 2026: CJC-1295 + ipamorelin's scientific confidence is now weak, not moderate; human CJC-1295 trials used DAC, per PubMed (PMID 16352683).
Before: moderate After: weak
What this does not mean: No new study was published, and the dose tiers are unchanged. Ipamorelin has its own human studies. PubMed lists no trial of this blend or of CJC-1295 without DAC.
Source: J Clin Endocrinol Metab 2006, Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Evidence
Corrected Oct 16, 2026: CJC-1295 + ipamorelin now reads Limited Research; the human CJC-1295 trials used the DAC form, per PubMed (PMID 16352683).
Before: well-researched After: limited-research
What this does not mean: Ipamorelin has its own human studies, and the dose tiers are unchanged. PubMed lists no trial of this blend or of CJC-1295 without DAC.
Source: J Clin Endocrinol Metab 2006, Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Dosing
Corrected Oct 14, 2026: the CJC-1295 trials dosed per kilogram with the DAC form, best tolerated at 30 or 60 mcg/kg, per PubMed (PMID 16352683).
What this does not mean: The dose tiers on this page are unchanged. The page had listed trial doses as 30 to 300 mcg, which mixed per-kilogram doses with flat community doses.
Source: J Clin Endocrinol Metab 2006, Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Safety
Corrected Oct 14, 2026: CJC-1295 + ipamorelin side effects now list serious events, including raised heart rate and a death in an IV ipamorelin study, per FDA.
Before: Flushing called common and benign; CJC-1295 said to have Phase I/II data; ipamorelin tolerability credited to Johansen 1999 and Raun 1998 After: Flushing reported as common in the community; FDA-cited serious events for CJC-1295 and IV ipamorelin listed; human CJC-1295 data credited to the DAC form; ipamorelin PK credited to Gobburu 1999
What this does not mean: No new study. FDA's Category 2 page holds this text; FDA words them as 'associated with' and says clinical data are limited. Human CJC-1295 data come from the DAC form; the No DAC form in this blend has no published human trial.
Source: FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 page, captured Oct 6, 2026) (opens in a new tab) · Saved copy
Peptide Schedule Research TeamReviewed Sep 24, 20269 Citations
References
- [1]Ipamorelin, the First Selective Growth Hormone Secretagogue (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Prolonged Stimulation of GH and IGF-I Secretion by CJC-1295 in Healthy Adults (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Human Volunteers (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Advances in the detection of growth hormone releasing hormone synthetic analogs (Memdouh et al., Drug Test Anal 2021) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry (J Pharm Biomed Anal 2026) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin (Drug Test Anal 2015) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Pharmacokinetic Evaluation of Ipamorelin and Other Peptidyl GH Secretagogues (opens in a new tab)PubMed 9879640PubMed
- Once-daily administration of CJC-1295, a long-acting GHRH analog, normalizes growth in the GHRH knockout mouse (Alba et al., Am J Physiol Endocrinol Metab 2006) (opens in a new tab)PubMed 16822960PubMed
- Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature (Pihoker et al., J Endocrinol 1997) (opens in a new tab)PubMed 9390009PubMed
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is CJC-1295 + Ipamorelin?
Hot. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 100s+. Community mentions on Reddit: High: hundreds of threads across r/peptides, r/PEDs, r/ster. Open r/Peptides (~95K members): most discussed GH stack (opens in a new tab).
1,295 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Very high search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.